Zoetis (NYSE:ZTS) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Zoetis (NYSE:ZTS) to a strong-buy rating in a report published on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for Zoetis’ Q4 2024 earnings at $1.44 EPS, FY2024 earnings at $5.96 EPS, Q1 2025 earnings at $1.50 EPS, Q2 2025 earnings at $1.68 EPS, Q3 2025 earnings at $1.72 EPS, Q4 2025 earnings at $1.57 EPS, FY2025 earnings at $6.48 EPS, FY2026 earnings at $7.15 EPS, FY2027 earnings at $7.84 EPS and FY2028 earnings at $8.49 EPS.

Other equities analysts have also recently issued research reports about the stock. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 14th. Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. BTIG Research boosted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Stifel Nicolaus boosted their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. Finally, Leerink Partners started coverage on Zoetis in a research report on Monday. They issued an “outperform” rating and a $215.00 target price for the company. Eleven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and an average price target of $220.80.

Zoetis Stock Performance

Shares of ZTS stock opened at $175.32 on Monday. Zoetis has a 12 month low of $144.80 and a 12 month high of $201.92. The stock has a market cap of $79.10 billion, a PE ratio of 32.95, a price-to-earnings-growth ratio of 2.71 and a beta of 0.89. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The company’s fifty day moving average price is $182.84 and its 200-day moving average price is $180.98.

Zoetis (NYSE:ZTS) last announced its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the previous year, the business posted $1.36 EPS. The company’s quarterly revenue was up 11.6% on a year-over-year basis. On average, equities analysts expect that Zoetis will post 5.9 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st were issued a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 0.99%. The ex-dividend date was Thursday, October 31st. Zoetis’s dividend payout ratio is 32.52%.

Institutional Investors Weigh In On Zoetis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Peapack Gladstone Financial Corp boosted its stake in Zoetis by 1.8% in the 3rd quarter. Peapack Gladstone Financial Corp now owns 77,004 shares of the company’s stock worth $15,045,000 after purchasing an additional 1,393 shares during the period. Tidal Investments LLC boosted its position in shares of Zoetis by 3.4% during the 3rd quarter. Tidal Investments LLC now owns 15,210 shares of the company’s stock valued at $2,972,000 after acquiring an additional 500 shares during the last quarter. Destination Wealth Management boosted its position in shares of Zoetis by 0.8% during the 3rd quarter. Destination Wealth Management now owns 123,844 shares of the company’s stock valued at $24,197,000 after acquiring an additional 1,027 shares during the last quarter. Wilmington Savings Fund Society FSB boosted its position in shares of Zoetis by 801.0% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 18,606 shares of the company’s stock valued at $3,635,000 after acquiring an additional 16,541 shares during the last quarter. Finally, World Investment Advisors LLC boosted its position in shares of Zoetis by 29.1% during the 3rd quarter. World Investment Advisors LLC now owns 34,236 shares of the company’s stock valued at $6,689,000 after acquiring an additional 7,709 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.